Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Chemed Corporation's third quarter results for 2025 indicate a mixed performance for its two main operating units, VITAS Healthcare and Roto-Rooter.</li><li>The quarter's outcomes largely aligned with management's expectations, highlighting both strengths and challenges within the company.</li><li>At VITAS, the hospice care segment, net revenue reached $407.7 million, a year-over-year increase of 4.2%.</li></ul>

Chemed Corporation's third quarter results for 2025 indicate a mixed performance for its two main operating units, VITAS Healthcare and Roto-Rooter.The quarter's outcomes largely aligned with management's expectations, highlighting both strengths and challenges within the company.At VITAS, the hospice care segment, net revenue reached $407.7 million, a year-over-year increase of 4.2%.

Chemed Inside: What You Need to Know About the New CON Gold Rush!

<ul><li>Chemed Corporation's second-quarter 2025 earnings highlight a mixed performance across its two major operating segments, VITAS and Roto-Rooter.</li><li>For VITAS, the hospice care segment, admissions showed a 4.9% increase when adjusted for the prior year acquisition, but the overall business grappled with significant Medicare cap challenges, particularly in Florida.</li><li>The Medicare cap billing limitations resulted in a $16.4 million hit during the quarter, attributed to a sharper than anticipated reimbursement rate hike in Florida compared to the national average.</li></ul>

Chemed Corporation's second-quarter 2025 earnings highlight a mixed performance across its two major operating segments, VITAS and Roto-Rooter.For VITAS, the hospice care segment, admissions showed a 4.9% increase when adjusted for the prior year acquisition, but the overall business grappled with significant Medicare cap challenges, particularly in Florida.The Medicare cap billing limitations resulted in a $16.4 million hit during the quarter, attributed to a sharper than anticipated reimbursement rate hike in Florida compared to the national average.

Chemed Corporation Bets Big on Florida & Digital—Will This Bold Strategy Pay Off?

<ul><li>Chemed Corporation's first-quarter results for 2025 provide a multifaceted view of the company's performance across its businesses.</li><li>Within its VITAS Healthcare unit, Chemed reported a solid overall performance, marked by a 15.1% increase in net revenue to $407.4 million compared to the same period the previous year.</li><li>This growth was fueled primarily by an 11.9% rise in days of care and a geographically weighted average increase in Medicare reimbursement rates.</li></ul>

Chemed Corporation's first-quarter results for 2025 provide a multifaceted view of the company's performance across its businesses.Within its VITAS Healthcare unit, Chemed reported a solid overall performance, marked by a 15.1% increase in net revenue to $407.4 million compared to the same period the previous year.This growth was fueled primarily by an 11.9% rise in days of care and a geographically weighted average increase in Medicare reimbursement rates.

Chemed Corporation: Expansion into New Markets & New Locations For A Competitive Edge!

<ul><li>Chemed Corporation's financial performance for the fourth quarter of 2024 presents a mixed picture with both its hospice segment, VITAS Healthcare, and its plumbing business, Roto-Rooter, showing varied trends.</li><li>During the quarter, VITAS continued to exhibit strong operating performance with admissions increasing by 3.5% year-over-year and its average daily census rising significantly by 14.6%.</li><li>This growth was largely driven by the $85 million acquisition of Covenant Health, which contributed positively to the quarter.</li></ul>

Chemed Corporation's financial performance for the fourth quarter of 2024 presents a mixed picture with both its hospice segment, VITAS Healthcare, and its plumbing business, Roto-Rooter, showing varied trends.During the quarter, VITAS continued to exhibit strong operating performance with admissions increasing by 3.5% year-over-year and its average daily census rising significantly by 14.6%.This growth was largely driven by the $85 million acquisition of Covenant Health, which contributed positively to the quarter.

Chemed Corporation: The Covenant Health Acquisition Is A Game-Changing Move!

<ul><li>Chemed Corporation's third-quarter 2024 earnings present a mixed performance across its two primary business segments: VITAS Healthcare and Roto-Rooter.</li><li>The company reports strong performance from VITAS, while Roto-Rooter is facing challenges.</li><li>VITAS Healthcare displayed robust growth in the quarter, primarily driven by increased admissions and the successful acquisition of Covenant Health.</li></ul>

Chemed Corporation's third-quarter 2024 earnings present a mixed performance across its two primary business segments: VITAS Healthcare and Roto-Rooter.The company reports strong performance from VITAS, while Roto-Rooter is facing challenges.VITAS Healthcare displayed robust growth in the quarter, primarily driven by increased admissions and the successful acquisition of Covenant Health.

Chemed Corporation: How Is The Management Tackling Roto-Rooter Challenges & Other Risks? -Major Drivers

United States

Chemed Corporation operates in the healthcare field through its subsidiary Vitas Healthcare Corporation.  The Company also maintains a presence in the residential and commercial repair-and-maintenance-service industry under the names Roto-Rooter and Service America Network Inc.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Chemed Corp (CHE US)

Chemed Inside: What You Need to Know About the New CON Gold Rush!

Chemed Corporation's third quarter results for 2025 indicate a mixed performance for its two main operating units, VITAS Healthcare and...

Baptista Research

Chemed Corporation Bets Big on Florida & Digital—Will This Bold Strategy Pay Off?

Chemed Corporation's second-quarter 2025 earnings highlight a mixed performance across its two major operating segments, VITAS and...

Baptista Research

Chemed Corporation: Expansion into New Markets & New Locations For A Competitive Edge!

Chemed Corporation's first-quarter results for 2025 provide a multifaceted view of the company's performance across its businesses. Within its...

Baptista Research

Chemed Corporation: The Covenant Health Acquisition Is A Game-Changing Move!

Chemed Corporation's financial performance for the fourth quarter of 2024 presents a mixed picture with both its hospice segment, VITAS...

Baptista Research

Chemed Corporation: How Is The Management Tackling Roto-Rooter Challenges & Other Risks? -Major Drivers

Chemed Corporation's third-quarter 2024 earnings present a mixed performance across its two primary business segments: VITAS Healthcare and...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)